Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)

SHE:300016 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,078	973.49	884.3	761.45	856.85	826.95
Other Revenue	16.3	10.07	6.42	4.43	3.06	0.39
Revenue	1,094	983.55	890.72	765.88	859.91	827.34
Revenue Growth (YoY)	18.05%	10.42%	16.30%	-10.93%	3.94%	1.00%
Cost of Revenue	599.52	524.59	485.37	365.47	327.99	280.52
Gross Profit	494.31	458.97	405.35	400.41	531.92	546.82
Selling, General & Admin	352.15	332.21	298.78	296.25	363.6	345.85
Research & Development	72.81	69.24	122.33	99.01	47.23	51.72
Other Operating Expenses	8.19	5.22	5.6	11.16	-5	11.61
Operating Expenses	435.25	405.73	430.35	405.53	404.37	409.49
Operating Income	59.06	53.24	-25	-5.12	127.55	137.33
Interest Expense	-57.38	-58.01	-53.14	-47.64	-44.19	-4.84
Interest & Investment Income	8.67	12.73	17.81	8.48	26.32	16.61
Currency Exchange Gain (Loss)	0.54	1.18	-2.76	-1.14	5.31	0.97
Other Non Operating Income (Expenses)	0.21	-0.74	-0.38	-1.57	-1.84	-1.41
EBT Excluding Unusual Items	11.1	8.4	-63.47	-47	113.15	148.66
Impairment of Goodwill	-	-	-31.82	-	-	-
Gain (Loss) on Sale of Investments	-3.9	-11.95	-13.96	20.54	13.9	19.41
Gain (Loss) on Sale of Assets	-1.15	0.12	0.89	0.1	0.13	-
Asset Writedown	-1.41	-1.14	-1.24	-0.58	-0.76	-4.34
Other Unusual Items	4.18	3.78	8.43	12.17	-4.06	10.11
Pretax Income	8.83	-0.78	-101.15	-14.76	122.36	173.84
Income Tax Expense	-3.17	-1.05	-17.95	-10.21	12.06	19.84
Earnings From Continuing Operations	12.01	0.27	-83.2	-4.55	110.29	154
Minority Interest in Earnings	12.07	13.38	11.44	15.83	15.22	20.71
Net Income	24.08	13.65	-71.76	11.28	125.51	174.7
Net Income to Common	24.08	13.65	-71.76	11.28	125.51	174.7
Net Income Growth	-	-	-	-91.01%	-28.16%	-48.98%
Shares Outstanding (Basic)	461	455	478	564	483	485
Shares Outstanding (Diluted)	461	455	478	564	483	485
Shares Change (YoY)	-4.58%	-4.88%	-15.21%	16.87%	-0.52%	-0.80%
EPS (Basic)	0.05	0.03	-0.15	0.02	0.26	0.36
EPS (Diluted)	0.05	0.03	-0.15	0.02	0.26	0.36
EPS Growth	-	-	-	-92.31%	-27.78%	-48.57%
Free Cash Flow	-67.41	61.63	-86.15	25.03	-39.03	3.9
Free Cash Flow Per Share	-0.15	0.14	-0.18	0.04	-0.08	0.01
Dividend Per Share	0.050	0.050	-	0.070	0.070	0.060
Dividend Growth	-	-	-	-	16.67%	-14.29%
Gross Margin	45.19%	46.66%	45.51%	52.28%	61.86%	66.09%
Operating Margin	5.40%	5.41%	-2.81%	-0.67%	14.83%	16.60%
Profit Margin	2.20%	1.39%	-8.06%	1.47%	14.60%	21.12%
Free Cash Flow Margin	-6.16%	6.27%	-9.67%	3.27%	-4.54%	0.47%
EBITDA	154.05	143.45	56.28	69.81	190.24	180.04
EBITDA Margin	14.08%	14.59%	6.32%	9.11%	22.12%	21.76%
D&A For EBITDA	94.99	90.21	81.28	74.93	62.7	42.7
EBIT	59.06	53.24	-25	-5.12	127.55	137.33
EBIT Margin	5.40%	5.41%	-2.81%	-0.67%	14.83%	16.60%
Effective Tax Rate	-	-	-	-	9.86%	11.41%
Revenue as Reported	1,094	983.55	890.72	765.88	859.91	827.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.